Here are five things to know:
1. The fund will link early stage drug discovery work with late stage development and large-scale clinical trials crucial to getting a new vaccine in the market.
2. Professionals are seeking funds from governments, foundations and the pharmaceutical industry in addition to travel and insurance industries.
3. Resources would be allocated toward manufacturing vaccines to globally accepted standards as well as early and mid-stage clinical trials. The trials were developed to test safety as well as proof-or-concept ensuring the vaccine will generate an immune response.
4. The fund would drive competitive proposal from institutions, scientists and biotech firms.
5. An independent panel of scientists and funders would be needed to review applications for financial support.
More articles on quality & infection control:
The American College of Surgeons responds to surgeon ratings: 4 things to know
9 things to know about ICER’s new drug assessment program
UK testing vital signs monitoring patch: 6 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.